Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667825 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 | |
| SCHEMBL6449707 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 | |
| SCHEMBL259443 | 1.00 | — | — | |
| SCHEMBL1960837 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 | |
| SCHEMBL8812128 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 | |
| SCHEMBL666947 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 | |
| SCHEMBL8812193 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 | |
| SCHEMBL98074 | 1.00 | — | — | |
| SCHEMBL21272039 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 | |
| SCHEMBL8812609 | 1.00 | HIF1A (0.53) | HIF1ATSHRDNM1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288316-A1 | METHOD OF USE FOR APOE PEPTIDES | ANJI PHARMA (US) LLC (US) | 2023-01-19 | — | — | WO | claimed |
| US-10653747-B2 | ApoE mimetic peptides and higher potency to clear plasma cholesterol | UAB RESEARCH FOUNDATION (US) | 2020-05-19 | — | — | US | claimed |
| US-20170209537-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | LIPIMETIX DEVELOPMENT, INC. | 2017-07-27 | — | — | US | claimed |
| EP-3189069-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB Research Foundation (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2016018665-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB RESEARCH FOUNDATION (US) | 2016-02-04 | — | — | WO | claimed |
| EP-4177263-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | Vitalixir (Beijing) Co., Ltd (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023288316-A1 | METHOD OF USE FOR APOE PEPTIDES | ANJI PHARMA (US) LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-107074923-B | APOE mimetics and higher potency for the removal of plasma cholesterol | UAB研究基金会 | 2021-08-03 | — | — | CN | disclosed |
| US-10653747-B2 | ApoE mimetic peptides and higher potency to clear plasma cholesterol | UAB RESEARCH FOUNDATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20170209537-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | LIPIMETIX DEVELOPMENT, INC. | 2017-07-27 | — | — | US | disclosed |
| EP-3189069-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB Research Foundation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016018665-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB RESEARCH FOUNDATION (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2006061696-A2 | BIPOLAR ELECTRODE BATTERIES AND METHODS OF MANUFACTURING BIPOLAR ELECTRODE BATTERIES | NISSAN MOTOR CO., LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0286427-B1 | Recording medium | CANON KK (JP) | 1993-12-22 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4954395-A | CONTAINING SURFACTANT AND FIXATIVE | CANON KABUSHIKI KAISHA (JP) | 1990-09-04 | — | — | US | disclosed |
| EP-0286427-A2 | Recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-10-12 | — | — | EP | disclosed |
| US-4680235-A | Recording material for ink jet printing | RICOH COMPANY, LTD. (JP) | 1987-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209537-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | APOB, LDLR, APOL1 | HIF1A 2616/4885TSHR 3195/4885DNM1 1342/4885 |
| US-10653747-B2 | ApoE mimetic peptides and higher potency to clear plasma cholesterol | APOB, LDLR, APOL1 | HIF1A 2616/4885TSHR 3195/4885DNM1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.